PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Tazobactam is a beta-lactamase inhibitor that protects piperacillin from degradation by beta-lactamases.
| Metabolism | Piperacillin is partially metabolized to a minor metabolite (desethyl piperacillin). Tazobactam is metabolized to a single inactive metabolite. Both are primarily eliminated renally. |
| Excretion | Piperacillin: ~70-80% renal (glomerular filtration and tubular secretion), ~10-20% biliary; Tazobactam: ~80-85% renal, ~10% biliary; both primarily excreted unchanged in urine; small fecal elimination (<5%). |
| Half-life | Piperacillin: 0.7-1.2 hours (normal renal function), extends to 2-6 hours in renal impairment; Tazobactam: 0.8-1.2 hours (normal renal function), extends to 4-8 hours in severe renal impairment; clinically relevant for dosing interval adjustments in renal dysfunction. |
| Protein binding | Piperacillin: ~16-30% bound to serum proteins (primarily albumin); Tazobactam: ~20-30% bound; both exhibit moderate binding. |
| Volume of Distribution | Piperacillin: Vd ≈ 0.18-0.3 L/kg (total body water distribution); Tazobactam: Vd ≈ 0.2-0.35 L/kg; distributes well into tissues, including bile, lung, kidney, and inflammatory fluids; limited CNS penetration unless meninges inflamed. |
| Bioavailability | Intravenous: 100% (only route); not orally bioavailable due to instability in gastric acid and poor absorption. |
| Onset of Action | Intravenous: immediate (minutes) for antibacterial effect; peak serum concentrations achieved by end of infusion. |
| Duration of Action | Approximately 6-8 hours for susceptible organisms; depends on renal function and MIC; typically dosed every 6 hours (or adjusted for renal impairment) to maintain free drug concentrations above MIC for >50% of dosing interval. |
| Molecular Weight | Piperacillin: 517.6 Da; Tazobactam: 300.3 Da; Sodium chloride: 58.44 Da (inert). For the compound, individual molecular weights apply. |
3.375 g (piperacillin 3 g / tazobactam 0.375 g) IV every 6 hours for 7-10 days; extended infusion dosing: 3.375 g IV over 4 hours every 8 hours.
| Dosage form | POWDER |
| Renal impairment | CrCl 20-40 mL/min: 2.25 g IV every 6 hours; CrCl <20 mL/min: 2.25 g IV every 8 hours; hemodialysis: 2.25 g IV every 12 hours with an additional dose after each dialysis session. |
| Liver impairment | No dose adjustment required for hepatic impairment; caution in severe hepatic impairment due to potential for bleeding risk (piperacillin may prolong PT). |
| Pediatric use | Neonates (<1 month): 90 mg/kg (piperacillin component) IV every 8 hours (for GA <37 weeks) or every 6 hours (for GA ≥37 weeks); Infants and children (≥1 month): 90 mg/kg (piperacillin component) IV every 6 hours; maximum dose 4.5 g (piperacillin 4 g / tazobactam 0.5 g) every 6 hours. |
| Geriatric use | Initiate with dosing based on renal function; monitor for bleeding risk (piperacillin can cause coagulopathy) and electrolyte disturbances (sodium load from sodium chloride); consider extended infusion for efficacy in elderly with renal impairment. |
| 1st trimester | Penicillins and beta-lactamase inhibitors are generally considered safe in pregnancy. Human data on piperacillin/tazobactam are limited, but no teratogenicity has been reported. Use only if clearly needed. |
| 2nd trimester | Considered safe; no known fetal risk. Excreted in low amounts across placenta. Avoid prolonged high-dose therapy if possible. |
| 3rd trimester | Generally safe; piperacillin crosses placenta. No reports of adverse fetal effects. Monitor for diarrhea or allergic reaction in mother. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Piperacillin crosses the placenta; tazobactam also crosses. Both achieve fetal serum concentrations approximately 20-50% of maternal levels. |
| Breastfeeding | Piperacillin and tazobactam are excreted into breast milk in low concentrations. No adverse effects in nursing infants have been reported. The American Academy of Pediatrics considers it compatible with breastfeeding. However, caution is advised due to potential for alteration of infant gut flora and rare allergic sensitization. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Pregnancy category B. No evidence of teratogenicity in animal studies; insufficient human data. Risk cannot be ruled out in first trimester; use only if clearly needed. No documented fetal harm with standard doses. |
| Fetal Monitoring | Monitor renal function, hepatic enzymes, and complete blood count (CBC) periodically. Assess for signs of hypersensitivity or superinfection. Fetal monitoring not routinely required but consider if maternal infection poses risk. |
| Fertility Effects | No known effect on human fertility. Animal studies showed no impairment of fertility at recommended doses. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | fluid replacement |
| Serious Effects |
Known hypersensitivity to piperacillin, tazobactam, or any other beta-lactam antibioticHistory of severe allergic reaction (e.g., anaphylaxis) to penicillins or cephalosporins
| Precautions | Serious and occasionally fatal hypersensitivity reactions (including anaphylaxis) have been reported., Clostridium difficile-associated diarrhea (CDAD) may occur., Bleeding manifestations have been reported, especially in patients with renal impairment or receiving high doses., Neuromuscular excitability or convulsions may occur with high doses or in patients with renal failure., Electrolyte disturbances due to sodium content., Renal function should be monitored periodically. |
| Food/Dietary | No clinically significant food interactions. However, the product contains sodium chloride; patients on sodium-restricted diets should consider the sodium content (approximately 135 mg NaCl per gram of piperacillin). Avoid alcohol during treatment due to potential disulfiram-like reaction (rare with penicillins). |
| Clinical Pearls | Piperacillin/tazobactam is a beta-lactam/beta-lactamase inhibitor combination with antipseudomonal activity. In the Duplex container, it is premixed with sodium chloride; ensure the container is at room temperature before administration. Adjust dose in renal impairment (CrCl <40 mL/min): for CrCl 20-40 mL/min, extend interval to q8h; for CrCl <20 mL/min, extend to q12h. Monitor for bleeding risk due to interference with platelet function (especially in renal failure). Contains sodium (approximately 5.6 mEq/g piperacillin); caution in patients with heart failure or hypertension. |
| Patient Advice | This medication is given through a vein (IV) and must be administered by a healthcare professional. · Tell your healthcare provider if you have kidney disease, heart failure, high blood pressure, or bleeding problems. · Report any signs of allergic reaction: hives, rash, difficulty breathing, or swelling of face/throat. · Inform your provider if you are taking blood thinners (e.g., warfarin) or methotrexate. · Complete the full course of treatment even if you feel better. |
Loading safety data…